SG11202005710YA - Methods and compositions for inducing an immune response against hepatitis b virus (hbv) - Google Patents

Methods and compositions for inducing an immune response against hepatitis b virus (hbv)

Info

Publication number
SG11202005710YA
SG11202005710YA SG11202005710YA SG11202005710YA SG11202005710YA SG 11202005710Y A SG11202005710Y A SG 11202005710YA SG 11202005710Y A SG11202005710Y A SG 11202005710YA SG 11202005710Y A SG11202005710Y A SG 11202005710YA SG 11202005710Y A SG11202005710Y A SG 11202005710YA
Authority
SG
Singapore
Prior art keywords
hbv
virus
inducing
compositions
methods
Prior art date
Application number
SG11202005710YA
Inventor
Daniel Boden
Helen Horton
Jean-Marc Edmond Fernand Marie Neefs
Soumitra Roy
Jerome Hubertina Henricus Victor Custers
Roland Christian Zahn
Markus Kalla
Pooter Dorien De
Original Assignee
Janssen Sciences Ireland Unlimited Co
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co, Bavarian Nordic As filed Critical Janssen Sciences Ireland Unlimited Co
Publication of SG11202005710YA publication Critical patent/SG11202005710YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
SG11202005710YA 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv) SG11202005710YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607439P 2017-12-19 2017-12-19
IB2017058148 2017-12-19
PCT/IB2018/060257 WO2019123250A1 (en) 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv)

Publications (1)

Publication Number Publication Date
SG11202005710YA true SG11202005710YA (en) 2020-07-29

Family

ID=65201641

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005710YA SG11202005710YA (en) 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv)

Country Status (12)

Country Link
EP (1) EP3727446A1 (en)
JP (1) JP2021506300A (en)
KR (1) KR20200100745A (en)
CN (1) CN111741766A (en)
AU (1) AU2018389786A1 (en)
BR (1) BR112020012273A2 (en)
CA (1) CA3086325A1 (en)
IL (1) IL275423A (en)
MA (1) MA51312A (en)
MX (1) MX2020006471A (en)
SG (1) SG11202005710YA (en)
WO (1) WO2019123250A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091513A1 (en) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION
EA202091516A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
AU2020298267A1 (en) * 2019-06-20 2022-02-17 Janssen Sciences Ireland Unlimited Company Self-replicating RNA molecules for hepatitis B virus (HBV) vaccines and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
EA002087B1 (en) 1997-04-03 2001-12-24 Электрофект Ас Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
CN1261807A (en) 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 Improved method for transferring nucleic acid into the striped muscle and combination therefor
WO2000002621A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
EP1550722B1 (en) 1999-05-17 2007-06-13 Crucell Holland B.V. Recombinant human adenovirus serotype 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
HU230198B1 (en) 2000-11-23 2015-10-28 Bavarian Nordic A/S Modified vaccinia ankara virus variant
WO2003048184A2 (en) 2001-12-04 2003-06-12 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
SI1497440T1 (en) 2002-04-25 2009-02-28 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
EA010828B1 (en) 2002-04-25 2008-12-30 Круселл Холланд Б.В. Recombinant adenovirus vectors and methods for the production thereof and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
JP4814800B2 (en) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Chimpanzee adenovirus vaccine carrier
PT1729848E (en) 2004-03-08 2015-08-28 Ichor Medical Systems Inc Improved apparatus for electrically mediated delivery of therapeutic agents
CN101248173A (en) * 2005-04-08 2008-08-20 墨尔本保健公司 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
CN105457157B (en) 2006-10-17 2020-04-14 因诺维奥制药公司 Electroporation device and method for mammalian cell electroporation using the same
EP2222336A2 (en) * 2007-10-29 2010-09-01 GENimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
WO2010060632A1 (en) 2008-11-27 2010-06-03 Bavarian Nordic A/S Promoters for recombinant viral expression
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
JP5882741B2 (en) 2009-02-02 2016-03-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Nucleic acid and amino acid sequences of simian adenovirus, vectors containing the same, and uses thereof
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
MX2012001592A (en) * 2009-08-07 2012-05-22 Transgene Sa Composition for treating hbv infection.
BR112013014712B1 (en) 2010-12-14 2021-03-02 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services first and second recombinant adenovirus vectors
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
EA201990114A1 (en) 2012-10-28 2019-09-30 Бавариан Нордик А/С PR13.5 PROMOTOR FOR SUSTAINABLE T-CELL AND HUMORAL IMMUNE REACTIONS
IL256869B (en) 2015-07-31 2022-07-01 Bavarian Nordic As Promoters for enhancing expression in poxvirus
WO2017121791A1 (en) * 2016-01-12 2017-07-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv
IL296595A (en) 2016-03-28 2022-11-01 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents

Also Published As

Publication number Publication date
CA3086325A1 (en) 2019-06-27
JP2021506300A (en) 2021-02-22
MA51312A (en) 2020-10-28
MX2020006471A (en) 2020-09-22
KR20200100745A (en) 2020-08-26
EP3727446A1 (en) 2020-10-28
AU2018389786A1 (en) 2020-06-18
CN111741766A (en) 2020-10-02
BR112020012273A2 (en) 2020-11-24
WO2019123250A1 (en) 2019-06-27
IL275423A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
HK1255502A1 (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
HK1255847A1 (en) Vaccines against hepatitis b virus
IL258697A (en) Crispr/cas-related methods and compositions for treating hepatitis b virus
ZA201906252B (en) Hepatitis b virus surface antigen inhibitor
IL275427A (en) Hepatitis b virus (hbv) vaccines and uses thereof
GB201708444D0 (en) Compositions and methods for inducing an immune response
HK1256869A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
HK1248278A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
IL275423A (en) Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
IL274298A (en) Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv)
IL275429A (en) Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
EP3463448A4 (en) Compositions and methods for generating an immune response to hepatitis b virus
HK1255379A1 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
IL290924A (en) Hepatitis b virus vaccines
GB201807932D0 (en) Compositions and methods for inducing an immune response
HK1259329A1 (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
EP3244922A4 (en) Methods of inducing an immune response to hepatitis c virus
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
GB201702193D0 (en) Hepatitis E virus vaccine
PL3244921T3 (en) An immunogenic vaccine against the hcv and/or hbv